Administration of Tumor Cell Chromatin to Immunosuppressed and Non-immunosuppressed Non-human Primates

For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by contaminants derived from the cell substrates used to produce those products. The present study addresses the issue of how risky DNA may be as a residu...

Full description

Saved in:
Bibliographic Details
Published inBiologicals Vol. 23; no. 3; pp. 221 - 224
Main Authors Wierenga, D.E., Cogan, J., Petricciani, J.C.
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.09.1995
Subjects
Animals
Chromatin - immunology
DNA, Neoplasm - administration & dosage
DNA, Neoplasm - adverse effects
DNA, Neoplasm - immunology
Humans
Immunocompromised Host
Macaca mulatta
Neoplasms - etiology
Primates
Tumor Cells, Cultured
Online AccessGet full text

Cover

More Information
Summary:For decades, developers and regulators of vaccines and other biological products have been concerned about the theoretical risk to patients posed by contaminants derived from the cell substrates used to produce those products. The present study addresses the issue of how risky DNA may be as a residual impurity by injecting both normal and immunosuppressed monkeys with 10 8genome equivalents of DNA from a human tumor cell line. After more than eight years of observation, none of the animals shows evidence of neoplastic disease. The results of this study along with clinical experiences with already approved products derived from continuous cell lines suggest that he benefits of using such cells for the production of biologicals far outweigh any theoretical risks associated with DNA.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:1045-1056
1095-8320
DOI:10.1006/biol.1995.0036